Effect of 9p21.3 coronary artery disease locus neighboring genes on atherosclerosis in mice

Circulation

Volumn 126, Issue 15, 2012, Pages 1896-1906

  Kim, Juyong Brian ^a,d   Deluna, Andres ^b,e   Mungrue, Imran N ^a,f   Vu, Christine ^b   Pouldar, Delila ^a   Civelek, Mete ^a   Orozco, Luz ^b   Wu, Judy ^a   Wang, Xuping ^a   Charugundla, Sarada ^a   Castellani, Lawrence W ^a   Rusek, Marta ^c   Jakobowski, Hieronim ^c   Lusis, Aldons J ^a,b  

^a Division of Cardiology   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^d STANFORD UNIVERSITY   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^f LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

5 methylthioadenosine phosphorylase; atherosclerosis; coronary artery disease; genetics; mice

Indexed keywords

CHOLESTEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; CHROMOSOME 9P; CONTROLLED STUDY; GENE CONTROL; METABOLISM; METHYLATION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DISEASE MODELS, ANIMAL; FEMALE; MALE; MICE; MICE, KNOCKOUT; MICROTUBULE-ASSOCIATED PROTEINS;

EID: 84867276514     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.111.064881     Document Type: Article

References (47)

1. McPherson R, Pertsemlidis A, Kavaslar N, Stewart A, Roberts R, Cox DR, Hinds DA, Pennacchio LA, Tybjaerg-Hansen A, Folsom AR, Boerwinkle E, Hobbs HH, Cohen JC. A common allele on chromosome 9 associated with coronary heart disease. Science. 2007;316:1488-1491.
2. Samani NJ, Erdmann J, Hall AS, Hengstenberg C, Mangino M, Mayer B, Dixon RJ, Meitinger T, Braund P, Wichmann HE, Barrett JH, Konig IR, Stevens SE, Szymczak S, Tregouet DA, Iles MM, Pahlke F, Pollard H, Lieb W, Cambien F, Fischer M, Ouwehand W, Blankenberg S, Balmforth AJ, Baessler A, Ball SG, Strom TM, Braenne I, Gieger C, Deloukas P, Tobin MD, Ziegler A, Thompson JR, Schunkert H. Genomewide association analysis of coronary artery disease. N Engl J Med. 2007;357:443-453.
3. Helgadottir A, Thorleifsson G, Manolescu A, Gretarsdottir S, Blondal T, Jonasdottir A, Sigurdsson A, Baker A, Palsson A, Masson G, Gudbjartsson DF, Magnusson KP, Andersen K, Levey AI, Backman VM, Matthiasdottir S, Jonsdottir T, Palsson S, Einarsdottir H, Gunnarsdottir S, Gylfason A, Vaccarino V, Hooper WC, Reilly MP, Granger CB, Austin H, Rader DJ, Shah SH, Quyyumi AA, Gulcher JR, Thorgeirsson G, Thorsteinsdottir U, Kong A, Stefansson K. A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science. 2007;316:1491-1493.
4. Serrano M, Lee H, Chin L, Cordon-Cardo C, Beach D, DePinho RA. Role of the ink4a locus in tumor suppression and cell mortality. Cell. 1996; 85:27-37.
5. Kamijo T, Zindy F, Roussel MF, Quelle DE, Downing JR, Ashmun RA, Grosveld G, Sherr CJ. Tumor suppression at the mouse ink4a locus mediated by the alternative reading frame product p19arf. Cell. 1997;91: 649-659.
6. Latres E, Malumbres M, Sotillo R, Martin J, Ortega S, Martin-Caballero J, Flores JM, Cordon-Cardo C, Barbacid M. Limited overlapping roles of p15(ink4b) and p18(ink4c) cell cycle inhibitors in proliferation and tumorigenesis. EMBO J. 2000;19:3496-3506.
7. Shmueli O, Horn-Saban S, Chalifa-Caspi V, Shmoish M, Ophir R, Benjamin-Rodrig H, Safran M, Domany E, Lancet D. Genenote: whole genome expression profiles in normal human tissues. C R Biol. 2003; 326:1067-1072.
8. Kadariya Y, Yin B, Tang B, Shinton SA, Quinlivan EP, Hua X, Klein-Szanto A, Al-Saleem TI, Bassing CH, Hardy RR, Kruger WD. Mice heterozygous for germ-line mutations in methylthioadenosine phosphorylase (MTAP) die prematurely of T-cell lymphoma. Cancer Res. 2009; 69:5961-5969.
9. Guevara NV, Kim HS, Antonova EI, Chan L. The absence of p53 accelerates atherosclerosis by increasing cell proliferation in vivo. Nat Med. 1999;5:335-339.
10. Mercer J, Figg N, Stoneman V, Braganza D, Bennett MR. Endogenous p53 protects vascular smooth muscle cells from apoptosis and reduces atherosclerosis in apoE knockout mice. Circ Res. 2005;96:667-674.
11. Merched AJ, Chan L. Absence of p21Waf1/Cip1/Sdi1 modulates macrophage differentiation and inflammatory response and protects against atherosclerosis. Circulation. 2004;110:3830-3841.
12. Diez-Juan A, Andres V. The growth suppressor p27(kip1) protects against diet-induced atherosclerosis. FASEB J. 2001;15:1989-1995.
13. Holdt LM, Beutner F, Scholz M, Gielen S, Gabel G, Bergert H, Schuler G, Thiery J, Teupser D. Anril expression is associated with atherosclerosis risk at chromosome 9p21. Arterioscler Thromb Vasc Biol. 2010;30:620-627.
14. Jarinova O, Stewart AF, Roberts R, Wells G, Lau P, Naing T, Buerki C, McLean BW, Cook RC, Parker JS, McPherson R. Functional analysis of the chromosome 9p21.3 coronary artery disease risk locus. Arterioscler Thromb Vasc Biol. 2009;29:1671-1677.
15. Liu Y, Sanoff HK, Cho H, Burd CE, Torrice C, Mohlke KL, Ibrahim JG, Thomas NE, Sharpless NE. Ink4/Arf transcript expression is associated with chromosome 9p21 variants linked to atherosclerosis. PLoS One. 2009;4:e5027.
16. Visel A, Zhu Y, May D, Afzal V, Gong E, Attanasio C, Blow MJ, Cohen JC, Rubin EM, Pennacchio LA. Targeted deletion of the 9p21 non-coding coronary artery disease risk interval in mice. Nature. 2010;464:409-412.
17. Gonzalez-Navarro H, Abu Nabah YN, Vinue A, Andres-Manzano MJ, Collado M, Serrano M, Andres V. P19(Arf) deficiency reduces macrophage and vascular smooth muscle cell apoptosis and aggravates atherosclerosis. J Am Coll Cardiol. 2010;55:2258-2268.
18. van Vlijmen BJ, van den Maagdenberg AM, Gijbels MJ, van der Boom H, HogenEsch H, Frants RR, Hofker MH, Havekes LM. Diet-induced hyperlipoproteinemia and atherosclerosis in apolipoprotein e3-leiden transgenic mice. J Clin Invest. 1994;93:1403-1410.
19. Fong MY, McDunn J, Kakar SS. Identification of metabolites in the normal ovary and their transformation in primary and metastatic ovarian cancer. PLoS One. 2011;6:e19963.
20. Evans AM, DeHaven CD, Barrett T, Mitchell M, Milgram E. Integrated, nontargeted ultrahigh performance liquid chromatography/electrospray ionization tandem mass spectrometry platform for the identification and relative quantification of the small-molecule complement of biological systems. Anal Chem. 2009;81:6656-6667.
21. Gu Y, Shore RE, Arslan AA, Koenig KL, Liu M, Ibrahim S, Lokshin AE, Zeleniuch-Jacquotte A. Circulating cytokines and risk of b-cell non-Hodgkin lymphoma: a prospective study. Cancer Causes Control. 2010; 21:1323-1333.
22. Fox J. Bootstrapping regression models. Applied Regression Analysis and Generalized Linear Models. Hamilton, ON, Canada: McMaster University; 2008.
23. Romanoski CE, Che N, Yin F, Mai N, Pouldar D, Civelek M, Pan C, Lee S, Vakili L, Yang WP, Kayne P, Mungrue IN, Araujo JA, Berliner JA, Lusis AJ. Network for activation of human endothelial cells by oxidized phospholipids: a critical role of heme oxygenase 1. Circ Res. 2011;109: e27-41.
24. Koomoa DL, Yco LP, Borsics T, Wallick CJ, Bachmann AS. Ornithine decarboxylase inhibition by alpha-difluoromethylornithine activates opposing signaling pathways via phosphorylation of both Akt/protein kinase B and p27Kip1 in neuroblastoma. Cancer Res. 2008;68: 9825-9831.
25. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med. 1998;338:1042-1050.
26. Antoniades C, Antonopoulos AS, Tousoulis D, Marinou K, Stefanadis C. Homocysteine and coronary atherosclerosis: from folate fortification to the recent clinical trials. Eur Heart J. 2009;30:6-15.
27. Perla-Kajan J, Jakubowski H. Paraoxonase 1 protects against protein n-homocysteinylation in humans. FASEB J. 2010;24:931-936.
28. Steed MM, Tyagi SC. Mechanisms of cardiovascular remodeling in hyperhomocysteinemia. Antioxid Redox Signal. 2011;15:1927-1943.
29. Wojcik OP, Koenig KL, Zeleniuch-Jacquotte A, Costa M, Chen Y. The potential protective effects of taurine on coronary heart disease. Atherosclerosis. 2010;208:19-25.
30. Murakami S, Kondo Y, Tomisawa K, Nagate T. Prevention of atherosclerotic lesion development in mice by taurine. Drugs Exp Clinical Res. 1999;25:227-234.
31. Zulli A, Lau E, Wijaya BP, Jin X, Sutarga K, Schwartz GD, Learmont J, Wookey PJ, Zinellu A, Carru C, Hare DL. High dietary taurine reduces apoptosis and atherosclerosis in the left main coronary artery: association with reduced CCAAT/enhancer binding protein homologous protein and total plasma homocysteine but not lipidemia. Hypertension. 2009;53: 1017-1022.
32. Sethupathy S, Elanchezhiyan C, Vasudevan K, Rajagopal G. Antiatherogenic effect of taurine in high fat diet fed rats. Indian J Exp Biol. 2002;40:1169-1172.
33. Schuller-Levis GB, Park E. Taurine and its chloramine: modulators of immunity. Neurochem Res. 2004;29:117-126.
34. Kanayama A, Inoue J, Sugita-Konishi Y, Shimizu M, Miyamoto Y. Oxidation of ikappa balpha at methionine 45 is one cause of taurine chloramine-induced inhibition of NF-kappa B activation. J Biol Chem. 2002;277:24049-24056.
35. Miao J, Zhang J, Zheng L, Yu X, Zhu W, Zou S. Taurine attenuates streptococcus uberis-induced mastitis in rats by increasing T regulatory cells. Amino Acids. 2012;42:2417-2428.
36. Schwab U, Torronen A, Toppinen L, Alfthan G, Saarinen M, Aro A, Uusitupa M. Betaine supplementation decreases plasma homocysteine concentrations but does not affect body weight, body composition, or resting energy expenditure in human subjects. Am J Clin Nutr. 2002;76:961-967.
37. Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, Dugar B, Feldstein AE, Britt EB, Fu X, Chung YM, Wu Y, Schauer P, Smith JD, Allayee H, Tang WH, DiDonato JA, Lusis AJ, Hazen SL. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature. 2011;472: 57-63.
38. Fyfe AI, Qiao JH, Lusis AJ. Immune-deficient mice develop typical atherosclerotic fatty streaks when fed an atherogenic diet. J Clin Invest. 1994;94:2516-2520.
39. Ducloux D, Challier B, Saas P, Tiberghien P, Chalopin JM. CD4 cell lymphopenia and atherosclerosis in renal transplant recipients. J Am Soc Nephrol. 2003;14:767-772.
40. Kaplan RC, Kingsley LA, Gange SJ, Benning L, Jacobson LP, Lazar J, Anastos K, Tien PC, Sharrett AR, Hodis HN. Low CD4 T-cell count as a major atherosclerosis risk factor in HIV-infected women and men. AIDS. 2008;22:1615-1624.
41. Hansson GK, Holm J, Holm S, Fotev Z, Hedrich HJ, Fingerle J. T lymphocytes inhibit the vascular response to injury. Proc Natl Acad Sci USA. 1991;88:10530-10534.
42. Lubin M, Lubin A. Selective killing of tumors deficient in methylthioadenosine phosphorylase: a novel strategy. PLoS One. 2009;4:e5735.
43. Basu I, Locker J, Cassera MB, Belbin TJ, Merino EF, Dong X, Hemeon I, Evans GB, Guha C, Schramm VL. Growth and metastases of human lung cancer are inhibited in mouse xenografts by a transition state analogue of 5-methylthioadenosine phosphorylase. J Biol Chem. 2011; 286:4902-4911.
44. Fuster JJ, Molina-Sanchez P, Jovani D, Vinue A, Serrano M, Andres V. Increased gene dosage of the Ink4/Arf locus does not attenuate atherosclerosis development in hypercholesterolaemic mice. Atherosclerosis. 2012;221:98-105.
45. Holdt LM, Sass K, Gabel G, Bergert H, Thiery J, Teupser D. Expression of chr9p21 genes CDKN2B (p15(INK4B)), cdkn2a (p16(INK4A), p14(ARF)) and MTAP in human atherosclerotic plaque. Atherosclerosis. 2011;214:264-270.
46. Zhou JX, Niehans GA, Shar A, Rubins JB, Frizelle SP, Kratzke RA. Mechanisms of g1 checkpoint loss in resected early stage non-small cell lung cancer. Lung Cancer. 2001;32:27-38.
47. Harismendy O, Notani D, Song X, Rahim NG, Tanasa B, Heintzman N, Ren B, Fu XD, Topol EJ, Rosenfeld MG, Frazer KA. 9p21 DNA variants associated with coronary artery disease impair interferon-gamma signalling response. Nature. 2011;470:264-268.